☆ 4.6 Article

A Risk Model for Patients with PSA-Only Recurrence (Biochemical Recurrence) Based on PSA and PSMA PET/CT: An Individual Patient Data Meta-Analysis

CANCERS (2022)

Related references

Note: Only part of the references are listed.

Article Radiology, Nuclear Medicine & Medical Imaging

Effect of 18F-DCFPyL PET/CT on the Management of Patients with Recurrent Prostate Cancer: Results of a Prospective Multicenter Registry Trial

Ur Metser et al.

Summary: The study indicates that PSMA PET can help detect additional sites of disease compared to conventional imaging in men with biochemical failure and suspected low-volume metastatic prostate cancer, leading to frequent changes in management strategies.

RADIOLOGY (2022)

Add to Collection

Article Oncology

Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy (ADOPT): study protocol for a randomised phase III trial

J. Janssen et al.

Summary: This phase III randomized controlled trial aims to assess the potential benefits of adding 6 months of ADT to MDRT in oligo-recurrent PCa patients, in order to improve metastases progression-free survival, toxicity, quality of life, and overall survival.

BMC CANCER (2022)

Add to Collection

Article Oncology

Phase III randomised controlled trial on PSMA PET/CT guided hypofractionated salvage prostate bed radiotherapy of biochemical failure after radical prostatectomy for prostate cancer (PERYTON-trial): study protocol

F. H. E. Staal et al.

Summary: The PERYTON trial aims to investigate whether increasing the biological effective radiation dose using hypofractionation can improve the treatment outcome of salvage external beam radiotherapy (sEBRT) for patients with biochemical recurrence (BCR) after radical prostatectomy. The use of PSMA PET/CT allows the exclusion of patients with oligometastases, avoiding ineffective treatment and unnecessary toxicity.

BMC CANCER (2022)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Event-free survival after 68Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC) patients eligible for salvage therapy

Francesco Ceci et al.

Summary: This study aimed to evaluate the incidence of clinically relevant events during follow-up in BCR prostate cancer patients who underwent PSMA-PET. The results showed that high PSA level and short PSAdt were predictors of higher event rates. PSMA-PET can predict the occurrence of clinically relevant events, and patients with negative PSMA-PET have a lower event rate.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

A Comprehensive Assessment of 68Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients

Monica Abghari-Gerst et al.

Summary: This study prospectively investigated the performance of prostate adenocarcinoma in patients with elevated PSA levels after initial therapy. The results showed that 68GaPSMA-11 PET can accurately detect the presence and disease burden of prostate cancer in patients who have undergone different treatments.

JOURNAL OF NUCLEAR MEDICINE (2022)

Add to Collection

Article Oncology

Metastasis-Free Survival and Patterns of Distant Metastatic Disease After Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET)-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After Prostatectomy

Constantinos Zamboglou et al.

Summary: This study aimed to evaluate the metastasis-free survival (MFS) and metastatic patterns after salvage radiation therapy (sRT) guided by prostate-specific membrane antigen positron emission tomography (PSMA-PET). The results showed that PSMA-PET detected distant metastases (DM) after sRT, with two distinct patterns: abdominal-lymphatic and distant. PSMA-PET-detected pelvic lymph node (PLN-PET) may serve as a new predictive parameter for MFS.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)

Add to Collection

Article Oncology

PSMA PET predicts metastasis-free survival in the setting of salvage radiotherapy after radical prostatectomy

Mike Wenzel et al.

Summary: The study evaluated the impact of PSMA PET findings before SRT on MFS in recurrent PCa patients after RP. The results showed that patients with locoregional positive PSMA PET had significantly worse MFS outcomes after SRT.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2022)

Add to Collection

Article Oncology

Comparison of [18F]PSMA-1007 with [68Ga]Ga-PSMA-11 PET/CT in Restaging of Prostate Cancer Patients with PSA Relapse

Manuela A. Hoffmann et al.

Summary: PSMA hybrid imaging can improve the diagnosis of recurrent prostate cancer. This study compared the diagnostic performance of [F-18]PSMA-1007 PET/CT and [Ga-68]Ga-PSMA-11 PET/CT by identifying PSA threshold levels. The results showed similar findings for both methods.

CANCERS (2022)

Add to Collection

Article Oncology

Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer

Dennie Meijer et al.

Summary: This study compared the oncological outcomes of patients who underwent PSMA-PET imaging before salvage radiation therapy (SRT) with those who did not. The study found that PSMA-PET/CT was associated with improved short-term oncological outcomes in patients with biochemical recurrence.

EUROPEAN UROLOGY ONCOLOGY (2022)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Impact of forced diuresis with furosemide and hydration on the halo artefact and intensity of tracer accumulation in the urinary bladder and kidneys on [68Ga]Ga-PSMA-11-PET/CT in the evaluation of prostate cancer patients

Christian Uprimny et al.

Summary: This study aimed to assess the impact of intravenous hydration and furosemide diuresis at different dosages on tracer accumulation and halo artefact in urinary system. Results showed that 20mg furosemide and 500ml sodium chloride significantly reduced bladder halo artefacts and tracer accumulation intensity in [Ga-68]Ga-PSMA-11-PET/CT scans.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)

Add to Collection

Review Urology & Nephrology

EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer

Philip Cornford et al.

Summary: The 2020 EAU-EANM-ESTRO-ESUR-SIOG guidelines provide evidence-based guidance on the treatment of relapsing, metastatic, and castration-resistant prostate cancer. These guidelines are continuously updated to reflect the latest research findings in the field.

EUROPEAN UROLOGY (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Performance of [68Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy-a multi-centre evaluation of 2533 patients

Ali Afshar-Oromieh et al.

Summary: The study aimed to evaluate the diagnostic performance of [Ga-68]Ga-PSMA-11 PET/CT in recurrent prostate cancer after prostatectomy in a large multicentre cohort. Results showed a clear association between higher PSA levels and Gleason Score with tumor detection on PET/CT, while age, amount of injected tracer, PSA doubling-time (PDA(DT)) or PSA velocity (PSA(Vel)) were not associated with pathological scans.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Early Injection of Furosemide Increases Detection Rate of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for 68Ga-PSMA-11 PET/CT

Christian Uprimny et al.

Summary: This study aimed to assess the impact of forced diuresis with early furosemide injection on the detection rate of local recurrence in prostate cancer patients with biochemical recurrence referred for Ga-68-PSMA-11 PET/CT, as well as determine whether the injection of furosemide shortly after tracer injection increases renal washout of Ga-68-PSMA-11.

JOURNAL OF NUCLEAR MEDICINE (2021)

Add to Collection

Article Oncology

Oligometastatic Disease Detection with 68Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer Patients (HSPC) with Biochemical Recurrence after Radical Prostatectomy: Predictive Factors and Clinical Impact

Carlos Artigas et al.

Summary: PSMA-PET/CT is an excellent imaging technique to detect OMD early in HSPC patients with BCR after RP, changing therapeutic management mostly into MDT.

CANCERS (2021)

Add to Collection

Article Oncology

Restaging the Biochemical Recurrence of Prostate Cancer with [68Ga]Ga-PSMA-11 PET/CT: Diagnostic Performance and Impact on Patient Disease Management

Aloyse Fourquet et al.

Summary: This study evaluated the diagnostic performance and therapy efficacy prediction of [Ga-68]Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence. The results showed high sensitivity and specificity, with significant impact on patient disease management and treatment efficacy, especially when guided by [Ga-68]Ga-PSMA-11 PET/CT.

CANCERS (2021)

Add to Collection

Article Oncology

Combining 68Ga-PSMA-PET/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A Retrospective Multicenter Study

Simon Kirste et al.

Summary: In this large cohort study, adding elective radiation therapy to Ga-68-PSMA-PET/CT-guided focal radiotherapy significantly improved biochemical-recurrence-free survival compared to focal radiotherapy alone, with lower toxicity.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

68Ga-PSMA PET/CT for Patients with PSA Relapse after Radical Prostatectomy or External Beam Radiotherapy

Finn Edler von Eyben et al.

Summary: This study aimed to summarize the clinical characteristics associated with Ga-68-PSMA PET/CT scans in patients restaged for PSA relapse after RP or EBRT. The number of positive sites on the scan significantly predicted overall survival, while risk score and regional locations were not significant.

DIAGNOSTICS (2021)

Add to Collection

Editorial Material Urology & Nephrology

The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study

Louise Emmett et al.

Summary: The combination of PSMA + MRI shows higher negative predictive value and sensitivity for detecting clinically significant prostate cancer compared to MRI alone, but with a lower specificity. Combined PSMA + MRI may help avoid unnecessary prostate biopsies in some men.

EUROPEAN UROLOGY (2021)

Add to Collection

Article Oncology

PSA and PSA Kinetics Thresholds for the Presence of 68Ga-PSMA-11 PET/CT-Detectable Lesions in Patients with Biochemical Recurrent Prostate Cancer

Manuela Andrea Hoffmann et al.

CANCERS (2020)

Add to Collection

Article Urology & Nephrology

68Ga-labelled PSMA ligand HBED-CC PET/CT imaging in patients with recurrent prostate cancer

Elif Neslihan Akdemir et al.

WORLD JOURNAL OF UROLOGY (2019)

Add to Collection

Article Oncology

The use of 68Ga-PET/CT PSMA to determine patterns of disease for biochemically recurrent prostate cancer following primary radiotherapy

Sheliyan Raveenthiran et al.

PROSTATE CANCER AND PROSTATIC DISEASES (2019)

Add to Collection

Review Urology & Nephrology

Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review

Thomas Van den Broeck et al.

EUROPEAN UROLOGY (2019)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT

Matthias Eiber et al.

JOURNAL OF NUCLEAR MEDICINE (2018)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0

Wolfgang P. Fendler et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)

Add to Collection

Article Multidisciplinary Sciences

Assessment of the prognostic value of the 8th AJCC staging system for patients with clinically staged prostate cancer; A time to sub-classify stage IV?

Omar Abdel-Rahman

PLOS ONE (2017)

Add to Collection

Article Oncology

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference

Mack Roach et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.